Kymera Therapeutics Inc
KYMRHealthcare|Biotechnology|USA
$119.36
+0.34 (+0.28%)
Tangible Book
$18.73
Financials
Financial Snapshot
Market Cap
$9.82B
Enterprise Value
$570.5M
Revenue (TTM)
$51.5M
Net Income (TTM)
$-315.0M
Cash & Equivalents
—
Net Cash/Share
$6.35
Free Cash Flow (TTM)
$-244.0M
Operating CF (TTM)
$-242.6M
Debt/Equity
0.05
Cash Runway & Burn Rate
Cash on Hand
$0.00
Quarterly Burn
$60.6M
Monthly Burn
$20.2M
Est. Runway
—
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $41.3M | $92.0M | $296.2M | $442.4M | $407.2M | $374.9M | $488.7M | $848.3M | $650.9M | |
| Operating Cash Flow | $-17.9M | $17.9M | $88.1M | $-128.9M | $-153.1M | $-102.8M | $-194.5M | $-232.9M | $-242.6M | |
| Free Cash Flow | $-19.2M | $17.4M | $79.0M | $-130.5M | $-155.9M | $-137.3M | $-207.3M | $-234.3M | $-244.0M | |
| Capital Expenditure | $-1.4M | $-532.0K | $-9.1M | $-1.6M | $-2.8M | $-34.5M | $-12.8M | $-1.4M | $-1.4M | |
| Financing Cash Flow | $52.9M | $34.9M | $289.3M | $250.3M | $153.0M | $4.2M | $608.9M | $990.7M | $1.01B |
R&D Spending
R&D (TTM)
$334.5M
R&D Intensity
649.8%
R&D Growth YoY
+5.7%
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $2.9M | $34.0M | $72.8M | $46.8M | $78.6M | $47.1M | $39.2M | $51.5M | |
| R&D Expense | $17.7M | $37.2M | $62.1M | $137.0M | $164.2M | $189.1M | $240.2M | $316.6M | $334.5M | |
| R&D % of Revenue | — | 1266.5% | 182.5% | 188.1% | 350.8% | 240.6% | 510.4% | 807.3% | 649.8% | |
| SG&A | $3.8M | $8.0M | $18.2M | $36.3M | $43.8M | $55.0M | $63.5M | $68.2M | $72.3M |
Income Statement
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $2.9M | $34.0M | $72.8M | $46.8M | $78.6M | $47.1M | $39.2M | $51.5M | |
| Cost of Goods Sold | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | $0.00 | $2.9M | $34.0M | $72.8M | $46.8M | $78.6M | $47.1M | $39.2M | $51.5M | |
| R&D | $17.7M | $37.2M | $62.1M | $137.0M | $164.2M | $189.1M | $240.2M | $316.6M | $334.5M | |
| SG&A | $3.8M | $8.0M | $18.2M | $36.3M | $43.8M | $55.0M | $63.5M | $68.2M | $72.3M | |
| Operating Income | $-21.5M | $-42.2M | $-46.3M | $-100.5M | $-161.3M | $-165.5M | $-256.7M | $-345.5M | $-355.3M | |
| Interest Expense | $-16.0K | $-46.0K | $-115.0K | $-175.0K | $-176.0K | $-196.0K | $-249.0K | $-370.0K | $-357.0K | |
| Pretax Income | $-21.5M | $-41.2M | $-45.6M | $-100.2M | $-154.8M | $-147.0M | $-223.9M | $-311.4M | $-315.0M | |
| Net Income | $-21.5M | $-41.2M | $-45.6M | $-100.2M | $-154.8M | $-147.0M | $-223.9M | $-311.4M | $-315.0M | |
| EPS (Diluted) | -1.07 | -1.37 | -3.15 | -2.09 | -2.87 | -2.52 | -2.98 | -3.69 | -3.57 | |
| EBITDA | $-21.2M | $-40.4M | $-43.7M | $-97.6M | $-151.7M | $-143.2M | $-216.2M | $-302.7M | $-306.4M | |
| Shares Out. (M) | 20.14 | 30.20 | 17.35 | 47.99 | 53.93 | 58.37 | 75.04 | 84.49 | 97.53 |
Balance Sheet
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $41.3M | $76.0M | $31.0M | $48.0M | $68.4M | $110.0M | $120.3M | $357.0M | $144.1M | |
| Marketable Securities | $0.00 | $15.9M | $265.2M | $394.4M | $338.8M | $264.9M | $368.5M | $491.3M | $506.8M | |
| Total Current Assets | $41.8M | $92.8M | $302.3M | $451.3M | $419.4M | $405.3M | $510.3M | $871.2M | $677.4M | |
| Total Assets | $44.2M | $116.7M | $487.2M | $605.9M | $603.1M | $575.8M | $978.0M | $1.74B | $1.67B | |
| Total Current Liabilities | $4.7M | $34.6M | $110.6M | $92.5M | $71.3M | $85.7M | $67.8M | $83.2M | $62.6M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $78.7M | $191.1M | $203.3M | $146.3M | $113.0M | $180.8M | $142.4M | $163.1M | $129.4M | |
| Stockholders' Equity | $-34.4M | $-74.4M | $283.9M | $459.6M | $490.2M | $395.0M | $835.6M | $1.58B | $1.54B | |
| Retained Earnings | $-35.2M | $-76.5M | $-128.8M | $-229.0M | $-383.8M | $-530.8M | $-754.6M | $-1.07B | $-1.14B |
Cash Flow Statement
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $-17.9M | $17.9M | $88.1M | $-128.9M | $-153.1M | $-102.8M | $-194.5M | $-232.9M | $-242.6M | |
| Capital Expenditure | $-1.4M | $-532.0K | $-9.1M | $-1.6M | $-2.8M | $-34.5M | $-12.8M | $-1.4M | $-1.4M | |
| Free Cash Flow | $-19.2M | $17.4M | $79.0M | $-130.5M | $-155.9M | $-137.3M | $-207.3M | $-234.3M | $-244.0M | |
| Investing Cash Flow | $-1.4M | $-16.5M | $-422.6M | $-99.8M | $20.5M | $139.9M | $-404.1M | $-521.1M | $-712.5M | |
| Financing Cash Flow | $52.9M | $34.9M | $289.3M | $250.3M | $153.0M | $4.2M | $608.9M | $990.7M | $1.01B | |
| Issuance of Stock | $0.00 | $0.00 | $196.7M | $243.1M | $149.8M | $0.00 | $596.6M | $928.9M | $691.6M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Issuance of Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Payments of Debt | $-295.0K | $-371.0K | $-554.0K | $-849.0K | $-1.1M | $-76.0K | $-1.6M | $-1.5M | $-1.6M | |
| Stock Based Comp. | $648.0K | $1.2M | $5.2M | $25.0M | $35.5M | $43.1M | $55.0M | $59.9M | $61.7M | |
| Net Change in Cash | $33.7M | $36.3M | $-45.2M | $21.5M | $20.4M | $41.3M | $10.3M | $236.8M | $54.1M |
Dilution Tracker
Shares outstanding grew 103.2% over 5 years — significant dilution
Shares Outstanding
98M
5-Year Share Growth
+103.2%
Stock Issuance (TTM)
$691.6M
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 20.14 | 30.20 | 17.35 | 47.99 | 53.93 | 58.37 | 75.04 | 84.49 | 97.53 | |
| YoY Change % | — | 49.9% | -42.5% | 176.6% | 12.4% | 8.2% | 28.6% | 12.6% | 15.4% | |
| Stock Issuance | $0.00 | $0.00 | $196.7M | $243.1M | $149.8M | $0.00 | $596.6M | $928.9M | $691.6M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $648.0K | $1.2M | $5.2M | $25.0M | $35.5M | $43.1M | $55.0M | $59.9M | $61.7M |
Margins & Profitability
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Margin % | 0.0% | -1438.5% | -136.1% | -138.0% | -344.4% | -210.6% | -545.4% | -881.2% | -690.2% | |
| Net Margin % | 0.0% | -1405.8% | -134.0% | -137.6% | -330.6% | -187.0% | -475.6% | -794.0% | -612.0% | |
| EBITDA Margin % | 0.0% | -1376.1% | -128.4% | -134.1% | -323.9% | -182.2% | -459.4% | -771.9% | -595.2% | |
| FCF Margin % | 0.0% | 592.1% | 232.2% | -179.2% | -333.0% | -174.7% | -440.5% | -597.6% | -474.0% | |
| ROE % | 0.0% | 0.0% | -43.5% | -27.0% | -32.6% | -33.2% | -36.4% | -25.8% | -27.1% | |
| ROA % | -48.5% | -51.3% | -15.1% | -18.3% | -25.6% | -24.9% | -28.8% | -22.9% | -24.0% | |
| R&D / Revenue | - | - | - | - | - | - | - | - | - |
Valuation
P/E (TTM)At Loss
HistoricalAt Loss / At Loss / At Loss
Industry Med.27.41
P/S213.52
Historical11.42 / 34.17 / 213.52
Industry Med.9.51
P/B6.37
Historical1.54 / 3.91 / 13.34
Industry Med.2.93
EV/EBITDA-30.19
Historical-74.19 / -14.56 / -2.22
Industry Med.13.14
EV/Revenue179.66
Historical5.66 / 32.29 / 215.08
Industry Med.8.71
P/FCF—
Historical5.78 / 10.44 / 16.97
Industry Med.27.54
Intrinsic Value Models
Tangible Book
$18.73
Net Current Assets
$6.670
Net-Net Working Capital
$6.35
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| PE Ratio | N/A | N/A | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | |
| PS Ratio | - | 0.00 | 31.60 | 41.82 | 28.76 | 18.90 | 64.16 | 167.69 | 213.52 | |
| PB Ratio | 0.00 | 0.00 | 9.71 | 7.12 | 2.80 | 3.58 | 3.12 | 4.01 | 6.37 | |
| EV/EBITDA | 0.00 | 0.00 | -56.72 | -29.16 | -6.49 | -7.86 | -10.22 | -18.38 | -30.19 | |
| EV/Revenue | 0.00 | 0.00 | 72.86 | 39.10 | 21.01 | 14.31 | 46.94 | 141.84 | 179.66 |
Analyst Estimates & Quality
Altman Z-Score
44.43
Safe
Piotroski F-Score
3
Weak
Beneish M-Score
-3.39
Unlikely Manipulator
Forward Estimates
| Metric | Current Year | Next Year | 2 Years Out |
|---|---|---|---|
| Revenue | $86.48M | $41.86M | $39.68M |
| Net Income | $-339.23M | $-433.30M | $-477.73M |
| EPS | -3.52 | -4.36 | -4.71 |
| Book Value per Share | 13.68 | 10.51 | 7.12 |
| Operating Cash Flow per Share | -3.27 | -3.81 | -3.61 |
| Operating CF | $-318.69M | $-372.00M | $-351.78M |
Dividends
Revenue Segments
By Business
| Segment | 2025 |
|---|---|
| Dedicated to reinventing the treatment of human disease through the development of innovative | $39.2M |
By Geography
| Segment | 2025 |
|---|---|
| United States | $39.2M |